Company Encyclopedia
View More
name
Brainstorm Cell
BCLI.US
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases.
1.946 T
BCLI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BrainStorm Cell Therapeutics Enters Securities Purchase Agreement

    BrainStorm Cell Therapeutics entered a securities purchase agreement with Labrys Fund II, L.P., issuing a $143,750 promissory note and receiving $121,500 after fees. The note is convertible into shares upon default. BrainStorm also announced a decrease in net loss for Q3 2025 and updates on its NurOwn Phase 3b ALS trial. Analysts rate BCLI stock as Hold with a $6.60 price target, but TipRanks' AI Analyst rates it as Underperform due to financial challenges and skepticism about NurOwn's efficacy.

    Tip Ranks·
    US
    BCLI
    +0.51%
    Tip Ranks·
    US
    BCLI
    +0.51%

    Brainstorm Cell | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BCLI
    +0.51%
    LB filings·
    US
    BCLI
    +0.51%

    16:30 ET BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    BrainStorm Cell Therapeutics announced its Q3 2025 financial results, reporting a net loss of $2.1 million, down from $2.7 million in Q3 2024. The company is advancing its Phase 3b clinical trial for NurOwn, with FDA clearance secured. The trial aims to enroll 200 participants to assess NurOwn's efficacy in treating ALS. BrainStorm plans a conference call for further updates.

    prnewswire·
    US
    BCLI
    +0.51%
    prnewswire·
    US
    BCLI
    +0.51%

    Mersana Therapeutics reports third quarter 2025 financial results

    Mersana Therapeutics Inc. reported a net loss of $7.5 million for Q3 2025, an improvement from a $11.5 million loss in Q3 2024. General and administrative expenses decreased to $6.3 million from $9.9 million. Cash and equivalents totaled $56.4 million as of September 30, 2025. The company will be acquired by Day One Biopharmaceuticals Inc., with the deal closing expected by January 2026.

    Reuters·
    US
    MRSN
    -1.36%
    Reuters·
    US
    MRSN
    -1.36%

    Brainstorm Cell Therapeutics Secures New Financing Agreement

    Brainstorm Cell Therapeutics (BCLI) has entered a financing agreement with Vanquish Funding Group, issuing a promissory note for $182,400 and receiving $155,000 after fees. The agreement allows for potential additional financing of up to $2 million over the next year. Analysts rate BCLI stock as a Hold with a $6.60 price target, but Spark's AI Analyst considers it an Underperform due to ongoing financial challenges and skepticism about its lead treatment, NurOwn. The company's market cap is $6.93M.

    Tip Ranks·
    US
    BCLI
    +0.51%
    Tip Ranks·
    US
    BCLI
    +0.51%
    © 2025 Longbridge｜Disclaimer